210 related articles for article (PubMed ID: 32274722)
1. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
2. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
3. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections.
Chhabra M; Wilson JC; Wu L; Davies GJ; Gandhi NS; Ferro V
Chemistry; 2022 Feb; 28(11):e202104222. PubMed ID: 34981584
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.
Brennan TV; Lin L; Brandstadter JD; Rendell VR; Dredge K; Huang X; Yang Y
J Clin Invest; 2016 Jan; 126(1):207-19. PubMed ID: 26649979
[TBL] [Abstract][Full Text] [Related]
5. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
6. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
Hammond E; Dredge K
Adv Exp Med Biol; 2020; 1221():539-565. PubMed ID: 32274726
[TBL] [Abstract][Full Text] [Related]
7. PI-88 and Related Heparan Sulfate Mimetics.
Chhabra M; Ferro V
Adv Exp Med Biol; 2020; 1221():473-491. PubMed ID: 32274723
[TBL] [Abstract][Full Text] [Related]
8. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.
Dredge K; Hammond E; Handley P; Gonda TJ; Smith MT; Vincent C; Brandt R; Ferro V; Bytheway I
Br J Cancer; 2011 Feb; 104(4):635-42. PubMed ID: 21285983
[TBL] [Abstract][Full Text] [Related]
9. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Vlodavsky I; Ilan N; Naggi A; Casu B
Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
[TBL] [Abstract][Full Text] [Related]
10. The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.
Singh P; Blatt A; Feld S; Zohar Y; Saadi E; Barki-Harrington L; Hammond E; Ilan N; Vlodavsky I; Chowers Y; Half E
Neoplasia; 2017 Mar; 19(3):175-184. PubMed ID: 28147305
[TBL] [Abstract][Full Text] [Related]
11. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity.
Koliesnik IO; Kuipers HF; Medina CO; Zihsler S; Liu D; Van Belleghem JD; Bollyky PL
Front Immunol; 2020; 11():132. PubMed ID: 32117279
[TBL] [Abstract][Full Text] [Related]
12. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
13. The Good and Bad Sides of Heparanase-1 and Heparanase-2.
Pinhal MAS; Melo CM; Nader HB
Adv Exp Med Biol; 2020; 1221():821-845. PubMed ID: 32274740
[TBL] [Abstract][Full Text] [Related]
14. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
15. Heparanase involvement in physiology and disease.
Nasser NJ
Cell Mol Life Sci; 2008 Jun; 65(11):1706-15. PubMed ID: 18425416
[TBL] [Abstract][Full Text] [Related]
16. Heparanase: Historical Aspects and Future Perspectives.
Khanna M; Parish CR
Adv Exp Med Biol; 2020; 1221():71-96. PubMed ID: 32274707
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.
Hammond E; Handley P; Dredge K; Bytheway I
FEBS Open Bio; 2013; 3():346-51. PubMed ID: 24251094
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
19. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans.
Gingis-Velitski S; Zetser A; Kaplan V; Ben-Zaken O; Cohen E; Levy-Adam F; Bashenko Y; Flugelman MY; Vlodavsky I; Ilan N
J Biol Chem; 2004 Oct; 279(42):44084-92. PubMed ID: 15292202
[TBL] [Abstract][Full Text] [Related]
20. The potential of heparanase as a therapeutic target in cancer.
Pisano C; Vlodavsky I; Ilan N; Zunino F
Biochem Pharmacol; 2014 May; 89(1):12-9. PubMed ID: 24565907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]